Investors Are Cashing In On Massive Shifts In The Healthcare Space

Something is afoot of late when taking a closer look at major indices such as the S&P 500 -- which is within a whisker of a new all-time high just as continued election uncertainty and rising COVID-19 cases worldwide -- seemingly should scare Wall Street into safer investments.

The reality is that investors are all looking past these near-term issues, and focusing instead on vaccines, a new U.S. administration and hopefully a return to somewhat normalcy in 2021. At the end, the rule of law, democracy and science will always prevail, and everyone is betting on this to be the case right now.

Speaking of science, in its 114 years of existence, the U.S. Food and Drug Administration has approved over 20,000 prescription drugs. It’s also given marketing clearance from more than 1,600 drugs specific to animals. It’s rather amazing to think about nearly 22,000 products to fight diseases and conditions in people and pets and yet there is still huge voids in health-care where prognoses remain extremely dim.

Against the backdrop of concerns about side effects and ineffectiveness of prescription drugs, there is growing demand for natural remedies to treat everything from cancer to the common cold. Consumers, particularly younger generations, are increasingly turning to alternative products – echinacea, turmeric and CBD (cannabidiol) for example – which can be found in the form of drinks, supplements, topicals and more, to avoid conventional drugs.

CBD, a non-psychoactive compound of cannabis and its cousin hemp, is particularly hot button today amid a surge in research to validate centuries of anecdotal evidence. When derived from hemp, CBD is fully legal throughout the U.S. since the passage of the 2018 Farm Bill, aligning the nation with dozens of other countries with vibrant hemp markets.

On that note, the popularity of CBD was the subject of a report this summer from Global Market Insights forecasting the global market to grow at a spectacular 52.7% compound annual growth rate to surpass $89 billion in 2026.

Nass Valley Gateway (CSE:NVG) (OTCPK:NSVGF) is a name to get to know in the market. The upstart has over 30,000 acres of hemp cultivation capacity at its disposal through a partnership with New Hope Labs and matching manufacturing capabilities to produce products sold under the Nass Valley Gardens moniker.

Nass Valley Gardens products include full- and broad-spectrum tinctures, softgels, gummies, topical lotions and pet products. In an industry where companies have been criticized for false advertising on product labels, Nass Valley stands head-and-shoulders over competition by putting its products through hundreds of analytic tests to provide full transparency demonstrating its hemp is grown from the highest quality, organic, non-GMO seed available today.

The company has also passed the rigorous vetting process of (NYSE:BABA), becoming one of the first CBD companies to get accepted into the ecommerce giant’s ecosystem that reaches billions of consumers worldwide. Moreover, is the world’s biggest business-to-business (B2B) marketplace, providing Nass Valley with an opportunity to expand it wholesale sales channels as well.

With these growing revenue streams, Nass Valley is targeting sales of $36 million in the next 12 months.

"We pride ourselves in utilizing only organic, safe and efficient practices to maintain the utmost integrity in producing products that underpin brand loyalty," said Michael Semler, CFO and Director of Nass Valley Gateway, in a phone conversation with "It is a competitive market, and we understand that consumer confidence is won through an unwavering commitment to quality products that deliver measurable results for our customers and their pets."

Semler is spot on with NVG having a finger on the pulse of the market as measured by investor interest growing. The company’s valuation is up more than 200% from September and the stock recently made a new 52-week high at $0.28.